Drug Profile


Alternative Names: IONIS-APO(a)Rx; IONIS-APOA Rx; ISIS-494372; ISIS-APO(a)RX; ISIS-APOA Rx

Latest Information Update: 14 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Class Antihyperlipidaemics; Antisense oligonucleotides
  • Mechanism of Action Apolipoprotein A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hyperlipoproteinaemias

Most Recent Events

  • 10 Dec 2015 Discontinued - Phase-II for Hyperlipoproteinaemia in Canada, Denmark, Germany, Netherlands, United Kingdom (SC)
  • 08 Nov 2015 Efficacy and adverse event data from a phase II trial in Hyperlipoproteinaemia presented at the American Heart Association Scientific Sessions (AHA-2015)
  • 07 Aug 2014 Phase-II clinical trials in Hyperlipoproteinaemia in Denmark and Germany (SC) (EudraCT2014-000701-13)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top